NESS ZIONA, Israel — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced that the last patient has completed the last scheduled study visit in the Company’s pivotal Phase 3 clinical trial (SGT-610-01) evaluating SGT-610 (patidegib gel, 2%) for the prevention...

SAN FRANCISCO, Calif. — Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced the initiation of the Phase Ia clinical trial of ACE-2223 to evaluate its safety, tolerability, and pharmacokinetics in healthy adults. The first-in-class, orally bioavailable small molecule, ACE-2223,...

PLAINSBORO, N.J. and BAGSVÆRD, Denmark — Novo Nordisk today announced that phase 3b results from the FRONTIER5 study of investigational denecimig were published in the Journal of Thrombosis and Haemostasis. The 26-week results showed that a direct switch to the subcutaneous denecimig pen injector from the emicizumab vial and syringe injection...